Chemeleon to Collaborate with Mayo Clinic to Finalize Ultra-Rapid Assay, Launches $10M Series A
Results in seconds rather than hours: Groundbreaking instrument-free assay nears completion
Chemeleon, a disruptive innovator in diagnostic technology, announced a collaboration with Mayo Clinic to complete development and clinical validation of their ultra-rapid, instrument-free assay poised to redefine point-of-care (POC) testing in emergency settings. This collaboration will focus on clinical optimization of Chemeleon’s flagship high-sensitivity cardiac troponin (hs-cTn) assay and explore the application of their platform technology to other acute care conditions beyond cardiac care. Coinciding with this milestone, the company has launched a $10M Series A funding round to help bring this transformative technology to market.
The ultra-rapid, POC assay leverages Chemeleon’s patented Binding-Induced Nanostructured Dynamic Surface (BINDS™) technology to deliver results in seconds rather than hours, dramatically accelerating clinical-decision making and transforming patient outcomes. Collaborating with Mayo Clinic enables enhanced clinical validation, diagnostic protocol optimization, and a clear path to adoption. “With Mayo Clinic’s deep clinical expertise, we’re accelerating a future where faster diagnosis can mean faster treatment for life-threatening conditions in and out of the emergency department,” said Brendan Walker, CEO of Chemeleon.
The Series A will fund clinical trials, FDA clearance, and initial market entry into a $15 billion acute care diagnostics market.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Last viewed contents
Thorlabs Brings Two Precision Thin Film Coating Facilities Online
Human environmental genome recovered in the absence of skeletal remains - Innovative approach permits the identification of DNA in samples of environmental material
Phoenix Black | Muffle furnaces | CEM
WITec Paper Award 2025 winners announced - This year’s prizes reward scientists for their excellent work in material analysis, battery research and medical science
QX600 Droplet Digital PCR System | Droplet Digital PCR systems | Bio-Rad Laboratories
Purdue biodefense technology project awarded $1.3 million NIH seed grant
Drug discovery within the patient - Genetic analysis of bacteria from humans and animals paves the way for new active ingredients
Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement - Offer price increased
Analytik Jena Opens Swiss Branch Office at the Endress+Hauser Headquarters
Adam Chong named new CEO of Rigaku Asia Pacific
Microscopy Today Innovation Award for novel X-ray lenses - High numerical aperture and sharp focus enable record resolution microscopy